Skip to main content
. Author manuscript; available in PMC: 2009 Nov 4.
Published in final edited form as: Cancer Cell. 2008 Nov 4;14(5):408–419. doi: 10.1016/j.ccr.2008.10.011

Figure 1. IL-1β transgenic mice develop gastric inflammation and dysplasia/carcinoma.

Figure 1

(A) The construct pBS/HKATPase/ß globin/IL-1β, which contains the mouse H+/K+-ATPase ß subunit gene and secreted form of hIL-1β cDNA, was microinjected into fertilized mouse oocytes. (B) Expression of hIL-1β in the stomachs of 4 and 12 month old IL-1β transgenic mice and control mice was determined using a human-specific IL-1β ELISA kit. Data are the mean ± SD of 10 mice. (C) Expression of human (transgenic) and mouse (endogenous) IL-1β mRNA in stomach as assessed by RT-PCR. (D) IL-1β transgenic mice develop gastric hyperplasia (upper lane) and gastritis (H&E staining, lower lane). (E) Male Line 19 IL-1β transgenic mice develop stomach cancer. (F) Activation and relocalization of β-catenin in gastric cancer of IL-1β transgenic mice. The stomach sections were stained with an anti-β-catenin antibody. Arrows show nuclear β-catenin+ cells (brown).